The Psoriasis Stratification to Optimize Relevant Therapy (PSORT) study assessed real-world levels of self-reported non-adherence to traditional systemic and biologic therapies used for psoriasis, and evaluated psychological and biomedical factors associated with non-adherence using multivariable analyses.
Conventional systemic and biologic therapies are highly effective in the treatment of moderate to severe psoriasis; however, treatment effectiveness is much lower in routine clinical practice than in clinical trials. Medication non-adherence is a missed opportunity for therapeutic benefit. Although patients go to their doctors for assistance in treating their symptoms, according to the study, approximately half of medications are not taken as prescribed.
This study, Psoriasis Stratification to Optimize Relevant Therapy (PSORT), assessed real-world levels of self-reported non-adherence to traditional systemic and biologic therapies used for psoriasis, and evaluated psychological and biomedical factors associated with non-adherence using multivariable analyses. Researchers defined non-adherence as either being intentional, in which patients knowingly make the decision not to follow the prescribed medication regimen, or unintentional, such as forgetting to take the medication. Of the 811 patients included in the study, 617 self-administered systemic therapy, and 22.4% were classified as non-adherent (12% intentionally, 10.9% unintentionally).
In the traditional systemic treatment group, (35.3%; n = 286), methotrexate was the most common treatment product (52%; n = 141). In the biologic treatement group, (64.7%, n = 525) adalimumab was the most common prescribed biologic (52.5%, n= 258), followed by ustekinumab (32.6%; n = 160) and etanercept (14.9%; n = 73). A significant proportion of patients using self-administered oral conventional systemic or subcutaneous biologic therapies (etanercept, adalimumab) were classified as non-adherent (22.4%); 12% were classified as intentionally and 10.9% were classified as unintentionally non-adherent.
The study reports that the multivariable model showed that being on a conventional systemic (odds ratio [OR], 4.34; 95% CI, 2.38-7.91), having strong medication concerns (OR, 1.92; 95% CI, 1.09-3.39), having a weaker routine or habit for taking systemic therapy (OR, 0.94; 95% CI, 0.91-0.97), a longer treatment duration (OR, 1.04; 95% CI, 1.02-1.06) and a younger age (OR, 0.97; 95% CI, 0.95-0.99), were associated with being classified as overall non-adherent.
The researchers concluded that a significant number of patients with psoriasis who were prescribed self-administered systemic therapies reported both intentional and unintentional non-adherence with their treatment regimen. This study emphasizes the need to assess adherence when determining factors that could be influencing treatment response, rather than the prescribed treatment simply being ineffective.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action
April 22nd 2024Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.